Portsmouth sells $30M Anthem Biosciences stake in block deal
What's the deal? Portsmouth Technologies LLCDealroom has a profile for this one. Try Dealroom → sold 30 lakh shares of Anthem BiosciencesDealroom has a profile for this one. Try Dealroom → at US$11.3 each in a block deal on the BSEDealroom has a profile for this one. Try Dealroom → on Friday, October 9, for a total of US$33.9M. The buyer's identity was not immediately available.
By the numbers: Portsmouth held 1,53,96,327 shares, a 2.73% stake, as of June 30, 2026. The sale represents roughly 19.49% of that holding, leaving an estimated 1,23,96,327 shares pending updated disclosures.
What's the context? The block deal price sat about 3.29% below Friday's close of US$11.7, which was down 1.33% on the day. The stock has gained 34.80% so far in 2026, giving the company a market capitalisation of US$6.59B.
The business: Anthem Biosciences reported total income of US$60.2M for the first quarter of FY27, down 21.3% year-on-year from US$76.5M. Profit after tax fell 11.7% to US$16.3M, while profit before tax dropped 22.4% to US$19.6M. Earnings per share came in at US$0.03, against US$0.03 a year earlier.
Why now? The sale follows a strong run since Anthem's market debut on July 21, 2025. The IPO was an offer for sale of up to 5.96 crore shares, worth about US$461M at the US$7.74 issue price.
The signal: Anthem listed at US$9.82, a 26.85% premium over its issue price. At Friday's close, shares traded roughly 51.11% above the IPO price — a gain that gave early holders like Portsmouth an exit opportunity even as quarterly earnings softened.
Read more: msn.com
Image credit: foteih
